AGP Executive Report
Last update: 8 hours agoGLP-1 Coverage Pressure: CVS is adding Eli Lilly’s Zepbound back to its formulary and covering an oral GLP-1, highlighting how cardiometabolic promise is colliding with payer cost and coverage friction. Safety Watch: A new study links GLP-1s to higher risk of hair loss, with regulators receiving hundreds of reports tied to semaglutide and tirzepatide. Antibiotic Stewardship: A Lancet analysis finds nearly all countries overuse “watch” antibiotics, raising drug-resistance risk and underscoring the need for smarter national targets. NHS Access Update: With Fampyra patents now expired, England’s NICE is clearing generic fampridine for NHS use in eligible people with multiple sclerosis. Cancer & Drug Approvals: GSK’s Jideytro (zidesamtinib) wins FDA approval for ROS1-positive NSCLC after prior therapy, while Summit Therapeutics shares new ivonescimab Phase 3 data as regulators weigh a decision. Healthcare Policy & Costs: The AHA pushes back on U.S. price-transparency proposals for imaging, warning of heavy admin burdens—especially for small and rural hospitals. Industry & Supply Chain: Sotera Health sets its Q2 earnings date, while Envirotainer expands cold-chain capacity in Navi Mumbai to support pharma logistics.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
